Exercise Training for Cardiovascular Disease
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, since the trial involves exercise training, you should consult with your doctor to ensure your medications are compatible with the exercise program.
What data supports the effectiveness of the treatment Exercise training for cardiovascular disease?
Is exercise training safe for people with cardiovascular disease?
How is exercise training different from other treatments for cardiovascular disease?
Exercise training is unique because it focuses on improving heart health through physical activity rather than medication or surgery. It involves a variety of exercises tailored to individual needs, aiming to enhance endurance, strength, and flexibility, which can improve quality of life and potentially reduce the risk of future heart problems.211121314
What is the purpose of this trial?
The development of type II diabetes (T2D) is strongly associated with obesity and both are well-established risk factors for cardiovascular disease. Knowing that vascular dysfunction is an early event in the development of cardiovascular disease in obese diabetic (OB-T2D) patients, The investigators set their long-term goal to define molecular mechanisms of vascular dysfunction and corrective strategies that target these mechanisms such as physical activity and weight loss. The investigators recently discovered that human adipose tissues release extracellular vesicles (adiposomes) that are efficiently captured by endothelial cells. Adiposomes are known to carry bioactive cargos such as proteins and micro RNAs; however, their lipid content has not been studied nor has their ability to transfer their lipid cargo to endothelial cells. In the current application, the investigators propose to investigate the role of adiposomes in communicating the unhealthy milieu, mainly dysregulated lipids, to endothelial cells in OB-T2D subjects. On top of these lipid species that the investigators propose to be carried by adiposomes are glycosphingolipids (GSLs). These lipids originate from the glycosylation of ceramides, a chemical process that is upregulated in the presence of inflammation and high glucose levels. Preliminary findings showed that in endothelial cells, GSL-rich adiposomes disturb plasma membrane structure and subsequently induce endothelial dysfunction. Moreover, the investigators found that preconditioning endothelial cells with high shear stress (which is an exercise mimetic) protected endothelial cells from the detrimental effects induced by adiposomes. Therefore, the central hypothesis is that adipose tissues in OB-T2D patients release GSL-loaded adiposomes that induce vascular endothelial dysfunction. The researchers propose that exercise and weight loss interventions (bariatric surgery) will restore adipose tissue homeostasis, reduce GSL-loaded adiposomes, and subsequently alleviate vascular risk in OB-T2D patients. The investigators will test the hypotheses by pursuing the following aims: aim 1: Investigate the role of GSL-rich adiposomes in the pathogenesis of endothelial dysfunction in OB-T2D adults; aim 2: Test the effectiveness of exercise training in reducing adiposome-mediated effects on vascular function; and aim 3: Examine changes in adiposome/caveolae axis following metabolic surgery and their association with vascular function.
Research Team
Abeer M Mohamed, MD, PhD
Principal Investigator
University of Illinois at Chicago
Eligibility Criteria
This trial is for adults aged 18-50 with obesity (BMI ≥ 35 kg/m2) and type II diabetes, who are not pregnant, can exercise moderately, and have no chronic heart, liver, kidney diseases or cancer. Smokers, drug/alcohol abusers, non-English speakers and those allergic to lidocaine cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Exercise Training
Participants undergo aerobic exercise training for 12 weeks, 3 times per week, 60 minutes per session
Follow-up
Participants are monitored for safety and effectiveness after treatment
Metabolic Surgery
Participants may undergo metabolic surgery to examine changes in adiposome/caveolae axis and their association with vascular function
Treatment Details
Interventions
- Exercise training
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Illinois at Chicago
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator